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One characteristic of Alzheimer’s disease (AD) is excessive accumulation of amyloid-β
(Aβ) in the brain. Aβ brain accumulation is, in part, due to a reduction in Aβ clearance
from the brain across the blood-brain barrier. One key element that contributes to Aβ
brain clearance is P-glycoprotein (P-gp) that transports Aβ from brain to blood. In AD,
P-gp protein expression and transport activity levels are significantly reduced, which
impairs Aβ brain clearance. The mechanism responsible for reduced P-gp expression
and activity levels is poorly understood. We recently demonstrated that Aβ40 triggers
P-gp degradation through the ubiquitin-proteasome pathway. Consistent with these
data, we show here that ubiquitinated P-gp levels in brain capillaries isolated from brain
samples of AD patients are increased compared to capillaries isolated from brain tissue
of cognitive normal individuals. We extended this line of research to in vivo studies
using transgenic human amyloid precursor protein (hAPP)-overexpressing mice (Tg2576)
that were treated with PYR41, a cell-permeable, irreversible inhibitor of the ubiquitin-
activating enzyme E1. Our data show that inhibiting P-gp ubiquitination protects the
transporter from degradation, and immunoprecipitation experiments confirmed that
PYR41 prevented P-gp ubiquitination. We further found that PYR41 treatment prevented
reduction of P-gp protein expression and transport activity levels and substantially
lowered Aβ brain levels in hAPP mice. Together, our findings provide in vivo proof that
the ubiquitin-proteasome system mediates reduction of blood-brain barrier P-gp in AD
and that inhibiting P-gp ubiquitination prevents P-gp degradation and lowers Aβ brain
levels. Thus, targeting the ubiquitin-proteasome system may provide a novel therapeutic
approach to protect blood-brain barrier P-gp from degradation in AD and other Aβ-based
pathologies.
Keywords: blood-brain barrier, P-glycoprotein, Alzheimer’s disease, brain capillaries, amyloid beta, ubiquitin-
proteasome system, ubiquitin, proteasome
INTRODUCTION
Accumulation of amyloid-β (Aβ) in the brain is a neuropathological hallmark of Alzheimer’s disease
(AD; Hardy and Selkoe, 2002). Increasing evidence suggests that Aβ brain accumulation is due to
impaired Aβ clearance from the brain (Zlokovic, 2005; Mawuenyega et al., 2010; Wang et al., 2016).
Several studies indicate a role for the blood-brain barrier efflux transporter P-glycoprotein (P-gp)
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in clearing Aβ from brain to blood: (1) P-gp transports
Aβ in vitro (Lam et al., 2001; Kuhnke et al., 2007; Hartz
et al., 2010); (2) in mice lacking P-gp, Aβ clearance is
decreased while Aβ brain levels are increased (Cirrito et al.,
2005; Yuede et al., 2016); (3) P-gp expression and transport
activity are reduced at the blood-brain barrier of several
AD mouse models (Hartz et al., 2010; Mehta et al., 2013;
Park et al., 2014); and (4) treating human amyloid precursor
protein (hAPP) mice with the PXR activator pregnenolone-
16-carbonitrile (PCN) induces P-gp expression and activity,
which restores Aβ transport and reduces Aβ brain levels
(Hartz et al., 2010). (5) Results of multiple studies from
different laboratories show that P-gp protein expression levels
at the human blood-brain barrier are significantly reduced
in AD patients (Wijesuriya et al., 2010; Jeynes and Provias,
2011; Carrano et al., 2014; Chiu et al., 2015). Consistent
with reduced P-gp protein expression levels, results of recent
PET imaging studies indicate compromised P-gp transport
activity in AD patients compared to age-matched cognitive
healthy individuals (van Assema et al., 2012; Deo et al.,
2014). Thus, existing studies support the conclusion that
blood-brain barrier P-gp is reduced in AD, however, more
insights into the mechanism that triggers this phenomenon are
needed to prevent P-gp loss in AD and improve Aβ brain
clearance.
In this regard, we recently reported that exposing isolated
rat brain capillaries to Aβ40 at concentrations similar to
those found in AD patients reduced P-gp protein expression
and transport activity levels in a time- and concentration-
dependent manner (Hartz et al., 2016). We showed that
Aβ40 triggers ubiquitination, internalization, and proteasomal
degradation of P-gp in isolated rat brain capillaries ex vivo
(Akkaya et al., 2015; Hartz et al., 2016). Collectively, these
results indicate that blood-brain barrier P-gp is part of an
Aβ clearance system and that P-gp expression and transport
activity levels are reduced in AD, suggesting a link between
high Aβ levels and reduced brain capillary P-gp levels in AD
pathology.
In the present study, we show that P-gp protein expression
and transport activity levels are reduced and that P-gp protein
is highly ubiquitinated in isolated human brain capillaries
from AD patients compared to P-gp in brain capillaries
isolated from age-matched cognitive normal individuals. We
extended our previous ex vivo findings to in vivo studies
with hAPP mice by blocking P-gp ubiquitination in hAPP
mice, which is the initial step of protein degradation mediated
by the ubiquitin-proteasome system. We used transgenic
hAPP-overexpressing mice (Tg2576) to test the hypothesis
that preventing P-gp reduction results in a reduction of Aβ
brain levels. We show here that inhibiting P-gp ubiquitination
in vivo with PYR41, a cell-permeable, irreversible inhibitor of
the ubiquitin-activating enzyme E1, prevents P-gp reduction at
the blood-brain barrier and significantly lowers Aβ brain levels
in vivo.
Together, our findings suggest that targeting the ubiquitin-
proteasome system by inhibiting ubiquitination protects brain
capillary P-gp and thereby lowers Aβ brain levels.
MATERIALS AND METHODS
Experimental Design and Statistical
Analysis
Sample size (animal numbers, number of brain capillaries,
number of human tissue samples) for individual experiments
were based on power analyses of preliminary data and previously
published data (Hartz et al., 2010, 2016, 2017), and are given
in the corresponding figure legends. Number of repetitions are
stated in the results section and the figure legends.
Results are presented as mean ± SEM. One-way analysis
of variance (ANOVA) was used to assess differences in group
means. Pre-planned pairwise post hoc tests were carried out when
the overall F test was significant, and the Bonferroni correction
was used to control the type 1 error rate. Statistical significance
was set at α = 0.05. Data were analyzed using GraphPad Prismr
statistical software (version 7.00; RRID:SCR_002798).
Animals
All animal experiments were approved by the University
of Kentucky Institutional Animal Care and Use Committee
(Protocol #2014-1233; PI: AMS Hartz) and carried out in
accordance with AAALAC regulations, the US Department of
Agriculture Animal Welfare Act, and the Guide for the Care and
Use of Laboratory Animals of the NIH.
Male transgenic hAPP-overexpressing mice (Tg2576 strain;
129S6.Cg-Tg(APPSWE)2576Kha; RRID:IMSR_TAC:2789;
n = 45) and corresponding male wild type (WT) mice (n = 15;
RRID:IMSR_TAC:2789) were purchased from Taconic Farms
(Germantown, NY, USA). On arrival, mice were 8-week old
with an average body weight of 27.1 ± 2.6 g (SD) for WT mice
and 29.9 ± 2.9 g (SD) for hAPP mice. Animals were single-
housed in an AALAC-accredited temperature- and humidity-
controlled vivarium (23◦C, 60%–65% relative humidity, 14:10
light-dark cycle) in cages connected to an EcoFlo Allentown
ventilation system (Allentown Inc., Allentown, NJ, USA).
Animals had ad libitum access to tap water and standard rodent
feed (Harlan Teklad Chow 2918, Harlan Laboratories Inc.,
Indianapolis, IN, USA) and were allowed to habituate to the
vivarium for at least 2 weeks after arrival before the start of
experiments.
Human Brain Tissue Samples
Human brain tissue samples (inferior parietal lobule) were
obtained from the UK-ADC tissue bank (IRB #B15-2602-
M). Case inclusion criteria for this study were enrollment
in the UK-ADC longitudinal autopsy cohort (Nelson et al.,
2007), a post-mortem interval ≤4 h, and a final consensus
diagnosis determined by a group of UK-ADC neuropathologists,
neuropsychologists, and neurologists. Cases were classified
into two groups: Group (1) cognitive normal (n = 3; a
classification of ‘‘normal’’ denotes a consensus diagnosis of
normal cognition and CERAD rating of ‘‘criteria not met’’) and
Group (2) AD patients (n = 3; Mirra et al., 1991). All brain
tissue samples were from female individuals, whose average
age at death was 85.5 ± 9.2 years (group 1, cognitive normal,
post-mortem interval: 1.5 h ± 0.3 h, Braak stage score: 1 ± 0)
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and 86.5 ± 9.2 years (group 2, AD, post-mortem interval:
3.5 h± 0.7 h, Braak stage score: 5.5± 0.7).
Chemicals
Antibodies against β-actin (ab8226; RRID:AB_306371), human
Aβ40 (ab12265; RRID:AB_298985), human Aβ42 (ab12267;
RRID:AB_298987), LRP (ab92544; RRID:AB_2234877), RAGE
(ab3611; RRID:AB_303947), APP (ab11118; RRID:AB_442855)
and 20S proteasome (ab109530; RRID:AB_10860339; antibody
raised against a synthetic peptide within the human proteasome
20S C2 unit (amino acids: 250–350; C terminal)), as well
as cyclosporine A (CSA; ab120114) were purchased from
Abcam (Cambridge, MA, USA). Modified Dulbecco’s phosphate
buffered saline (DPBS; with 0.9 mM Ca2+ and 0.5 mM
Mg2+) was purchased from HyClone (Logan, UT, USA).
CompleteTM protease inhibitor was purchased from Roche
(Mannheim, Germany). C219 antibody against P-gp was
purchased from ThermoFisher (MA126528; RRID:AB_795165;
Waltham, MA, USA). Fluorescein-hAβ42 [fluorescein-Aβ(1–42)]
was purchased from rPeptide (Bogart, GA, USA). [N- (4-
nitrobenzofurazan-7-yl)-D-Lys8]-cyclosporine A (NBD-CSA)
was custom-synthesized by R. Wenger (Basel, Switzerland;
Wenger, 1986). PSC833 was a kind gift from Novartis
(Basel, Switzerland). PYR41, CelLyticTM M, Ficollr PM
400, bovine serum albumin and all other chemicals were
purchased at the highest grade from Sigma-Aldrich (St. Louis,
MO, USA).
PYR41 Dosing
Table 1 shows the dosing regimen for this in vivo study. Mice
were dosed as follows: Group 1: WT mice (n = 15) received i.p.
vehicle every third day and p.o. vehicle on both days between i.p.
vehicle injections. Group 2: hAPP mice (n = 15) also received
i.p. vehicle every third day and p.o. vehicle on both days between
i.p. vehicle injections. Group 3: hAPP-PYR41 mice (n = 15) were
dosed every third day with 2 mg/kg PYR41 by i.p. injection
and received p.o. vehicle on days between PYR41 treatment.
Group 4: hAPP-PYR41/CSA mice (n = 15) were dosed every
third day with 2 mg/kg PYR41 by i.p. injection and received
25 mg/kg CSA via oral gavage on both days between doses of
PYR41.
Blood Collection
Blood samples were collected by facial vein bleeding 24 h
prior to the start of the first dose to obtain control values.
Twenty-four hours after the last dose, mice were euthanized
by CO2 inhalation, decapitated and trunk blood was collected
in heparinized blood collection tubes. Plasma was obtained by
centrifugation at 5000× g for 15 min at 4◦C and stored at−80◦C
until further analysis.
Brain Capillary Isolation
Brain capillaries were isolated using a modified method
previously described elsewhere (Hartz et al., 2012). Briefly, mice
were euthanized with CO2 followed by decapitation. Brains
were removed, cleaned, dissected and homogenized in DPBS
containing Ca2+/Mg2+ and supplemented with 5 mMD-glucose TA
B
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and 1 mM sodium pyruvate. Ficollr PM 400 was added to
the homogenized brains (final concentration 15%) and the
homogenate was centrifuged (5800 g, 20 min, 4◦C). After
centrifugation, the capillary-enriched pellet was collected and
resuspended in 1% BSA-DPBS. The capillary suspension was first
passed through a 300 µm nylon mesh and then passed over a
glass bead column using 1% BSA-DPBS. Capillaries adhering
to the glass beads were washed off and collected by agitation
in 1% BSA-DPBS. After centrifugation (1500 g, 3 min, 4◦C),
the capillary pellet was washed three times with DPBS (no
BSA), collected, and used for experiments or crude membrane
isolation.
Brain Capillary Crude Membrane Isolation
Brain capillary crude membranes were isolated as previously
described (Hartz et al., 2012). Freshly isolated brain capillaries
were homogenized in lysis buffer (CelLyticTM M, Sigma-
Aldrich, St. Louis, MO, USA) containing CompleteTM protease
inhibitor. Homogenates were centrifuged to separate the
membrane fraction from organelles and debris (10,000 g,
15 min, 4◦C), and the resulting membrane-containing
supernatant was centrifuged to pellet capillary crude membranes
(100,000 g, 90 min, 4◦C). The resulting pellet containing brain
capillary crude membranes was resuspended and stored at
−80◦C.
Aβ Immunostaining of Brain Capillaries
Aβ immunostaining of mouse brain capillaries was performed as
previously described (Hartz et al., 2010). Briefly, isolated mouse
brain capillaries were fixed with 3% paraformaldehyde/0.25%
glutaraldehyde for 30 min at room temperature. After washing
with PBS, capillaries were permeabilized with 0.5% Triton
X-100 for 30 min and washed with PBS. Capillaries were
blocked with 1% BSA/DPBS for 60 min and incubated
overnight at 4◦C with a 1:250 (4 µg/ml) dilution of rabbit
polyclonal antibody to human Aβ1–40 (hAβ40; ab12265,
Abcam, Cambridge, MA, USA; RRID:AB_298985) or rabbit
polyclonal to human Aβ1–42 antibody (hAβ42; ab12267;
Abcam, Cambridge, MA, USA; RRID:AB_298987). Capillaries
were washed with 1% BSA/PBS and incubated with Alexa-
Fluor 488-conjugated goat anti-rabbit IgG (1:1000, 1 µg/ml;
Invitrogen, Carlsbad, CA, USA; RRID:AB_2576217) for 1 h at
37◦C. Nuclei were counterstained with 1 µg/ml 4,6-diamidino-
2-phenylindole (DAPI; MilliporeSigma, Burlington, MA, USA;
RRID:SCR_014366). Aβ immunofluorescence was visualized
with confocal microscopy (Leica TCS SP5 confocal microscope,
63× water objective, NA 1.2, Leica Instruments, Wetzlar,
Germany).
From each treatment group, confocal images
of seven capillaries were acquired. Aβ membrane
immunofluorescence for each capillary was quantitated with
ImageJ software v1.48 as previously described (Hartz et al.,
2010). A 10 × 10 grid was superimposed on each image, and
fluorescence measurements of capillary membranes were taken
between intersecting grid lines. Fluorescence intensity for each
capillary was the mean of three measurements per capillary.
Aβ ELISA
Human Aβ40 and Aβ42 levels were quantitated in plasma and
brain samples by ELISA (KHB3482 (Sensitivity: <6 pg/ml) and
KHB3442 (Sensitivity: <10 pg/ml) from Invitrogen, Camarillo,
CA, USA) according to the manufacturer’s protocol.
Plasma Samples
Blood samples were collected from control, PYR41 and
PYR41/CSA-treated hAPP transgenic mice. Plasma was obtained
from blood samples by centrifugation at 5000 g for 5 min at
4◦C, and then diluted with standard diluent buffer provided
with the ELISA kit. To determine hAβ40 levels, samples
were diluted 1:50; to determine hAβ42 levels, samples were
diluted 1:4.
Brain Samples
To determine brain hAβ40 and hAβ42 levels, brain tissue samples
were homogenized in guanidine Tris-HCl buffer (5 M, pH 8)
to extract Aβ. To determine hAβ40 levels, samples were diluted
1:20 in DPBS buffer containing 5% BSA and 0.03% Tween-20;
to determine hAβ42 levels, samples were diluted 1:5. Diluted
samples were centrifuged at 16,000 g for 20 min at 4◦C; the
supernatant was used for ELISA analysis.
Absorbance was measured at 450 nm using a SynergyTM
H1 Hybrid Multi-Mode Reader (BioTek, Winooski, VT, USA).
A standard curve was plotted using Gen5TM software v2.07 to
determine the concentration of hAβ40 and hAβ42 in plasma and
brain samples; values at 450 nm were corrected for background
absorbance; four parameter logistic ELISA curve fitting was
selected.
Western Blotting
Protein expression levels from various tissues were determined
by Western blotting as described previously (Hartz et al.,
2010, 2016). Protein concentration of brain capillary crude
membranes was measured with the Bradford assay. Western
blots were performed by using the Invitrogen NuPager
Bis-Tris electrophoresis and blotting system. After protein
electrophoresis and transfer, blotting membranes were blocked
and incubated overnight with the primary antibody as indicated.
Membranes were washed and incubated for 1 h with horseradish
peroxidase-conjugated ImmunoPure secondary IgG antibody
(1:5000, 0.15 µg/ml; Thermo Fisher Scientific, Waltham,
MA, USA). Proteins were detected with SuperSignal West
Pico Chemoluminescent Substrate (Thermo Fisher Scientific,
Waltham, MA, USA). Protein bands were visualized and
recorded with a Bio-Rad ChemiDoc XRS+ gel documentation
system (Bio-Rad Laboratories, Hercules, CA, USA). Image Lab
5.0 software from Bio-Rad Laboratories (RRID:SCR_014210)
was used for densitometric analyses of band intensities
and digital molecular weight analyses; the molecular weight
marker was RPN800E (GE Healthcare, Chalfont St. Giles,
Buckinghamshire, UK). Linear adjustments of contrast and
brightness were applied to entire Western blot images. None
of the Western blots shown were modified by nonlinear
adjustments.
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Immunoprecipitation
Immunoprecipitation was carried out as previously reported
(Hartz et al., 2016). Briefly, brain capillaries were homogenized
in lysis buffer (CelLyticTM M, Sigma-Aldrich, St. Louis, MO,
USA) containing CompleteTM protease inhibitor. Samples were
centrifuged to separate cellular membranes from organelles and
debris (10,000 g, 15 min, and 4◦C). Protein concentration of the
supernatants was determined by Bradford assay.
Anti-P-gp antibody (C219, EMD Millipore, Billerica, MA,
USA) was coupled with Pierce Protein A/G Plus Agarose
(Thermo Fisher Scientific, Waltham, MA, USA) beads overnight
at 4◦C in TBST (20 mM Tris (pH 8.0), 170 mM NaCl,
0.05% Tween 20) supplemented with 1% BSA. The immune
complex was added to the cell lysate and incubated for 3 h
at 4◦C. Beads were washed with lysis buffer (10 mM Tris
(pH 7.5), 2 mM EDTA, 100 mM NaCl, 1% NP-40, 50 mM
NaF, 1 mMNa3VO4) containing CompleteTM protease inhibitor.
For ubiquitin immunoprecipitations, the PierceTM Ubiquitin
Enrichment Kit (#89899; Thermo Fisher Scientific, Waltham,
MA, USA) was used according to the manufacturer’s protocol.
Immunoprecipitated proteins were eluted from agarose beads
(IP: P-gp) or the ubiquitin affinity resin (IP: ubiquitin) with
NuPAGE LDS sample buffer and heated at 70◦C for 10 min. IP
samples were resolved by SDS-PAGE and analyzed by Western
blotting as described above.
Simple Western Assay
Human brain capillary membrane samples were mixed with
WesTM sample buffer and analyzed with a Simple Western
assay designed for the WesTM instrument by ProteinSimple as
previously described (San Jose, CA, USA; Hartz et al., 2016). All
steps of the WesTM Master Kit assay were performed according
to the manufacturer’s protocol. Briefly, glass microcapillaries
were loaded with stacking and separation matrices followed by
sample loading. During capillary electrophoresis, proteins were
separated by size and then immobilized to the capillary wall. P-gp
and β-actin were identified with primary antibodies against P-gp
(1:100, 3 µg/ml, C219, MA126528, ThermoFisher, Waltham,
MA, USA; RRID:AB_795165) and β-actin (1:150, 5 µg/ml,
ab8226, Abcam, Cambridge, MA, USA; RRID:AB_306371),
respectively, followed by immunodetection using WesTM Master
Kit HRP conjugated anti-mouse secondary antibody and
chemiluminescent substrate. Using Compass V. 2.6.5 software,
electropherograms were generated for each sample and each
protein (P-gp and β-actin). The area under the curve (AUC),
which represents the signal intensity of the chemiluminescent
reaction was analyzed for P-gp and β-actin. Values given for P-gp
protein expression were normalized to β-actin.
P-gp Transport Assay
To determine P-gp transport activity, freshly isolated brain
capillaries from WT and hAPP mice were incubated for 1 h at
room temperature with the fluorescent P-gp-specific substrate
NBD-CSA (2 µM in PBS buffer; Hartz et al., 2004, 2008,
2010). To assess P-gp-mediated Aβ transport, isolated brain
capillaries were incubated for 1 h at room temperature with 5µM
fluorescein-hAβ42 in DPBS buffer (Hartz et al., 2010). For each
treatment, images of 10 capillaries were acquired by confocal
microscopy using the 488 nm line of an argon laser (Leica
Instruments, Wetzlar, Germany) of a Leica TCS SP5 confocal
microscope with a 63× 1.2 NA water immersion objective.
Images were analyzed by quantitating NBD-CSA fluorescence
in the capillary lumen using Image J v.1.48v (Wayne Rasband,
NIH, USA; RRID:SCR_003070). Specific, luminal NBD-CSA
fluorescence was taken as the difference between total luminal
fluorescence and fluorescence in the presence of the P-gp-specific
inhibitor PSC833 (5 µM; Hartz et al., 2004, 2008, 2010).
RESULTS
P-gp Ubiquitination Levels Are Increased
in Brain Capillaries From AD Patients
Several studies have provided evidence showing that P-gp
expression levels at the blood-brain barrier are reduced in AD
patients compared to control individuals (Wijesuriya et al.,
2010; Jeynes and Provias, 2011; Carrano et al., 2014; Chiu
et al., 2015). To assess P-gp protein expression in human brain
capillaries, we utilized a recently established protocol to isolate
brain capillaries from fresh human frontal cortex tissue (Hartz
et al., 2017). Figure 1 shows representative confocal images
of a brain capillary isolated from brain tissue of a cognitive-
normal individual (CNI) immunostained for P-gp (Figure 1A).
The negative control (no primary antibody) shows no signal
for P-gp (Figures 1B,B1: green channel; B2: blue channel;
B3: overlay of green and blue channel; B4: transmitted light
channel).
We utilized the Simple WesternTM assay to quantitate P-gp
protein levels in isolated human brain capillaries. This novel
assay allows protein quantitation at 10-fold higher sensitivity
and better reproducibility compared to Western blotting (Hartz
et al., 2017). The assay is based on automated microcapillary
electrophoresis; data robustness was tested at the NIH (Chen
et al., 2015). Figure 1C shows that a band for P-gp was
detected in membrane samples of brain capillaries isolated
from CNI patients that was between the 180 kDa and
230 kDa bands of the molecular weight marker. Consistent
with previous studies (Wijesuriya et al., 2010; Jeynes and
Provias, 2011; Carrano et al., 2014; Chiu et al., 2015), we
found that P-gp protein levels in brain capillary samples
from AD patients were significantly lower compared to brain
capillaries from cognitive normal individuals (CNI; Figure 1C);
β-actin served as loading control. Figure 1D shows the
electropherogram of the P-gp microcapillary electrophoresis.
Analysis of this electropherogram revealed that the P-gp
band peaked at 199.8 ± 2.5 kDa; the peak for β-actin was
detected at 49.7 ± 2.6 kDa. The bandwidth for P-gp was
24.8 ± 1.9 kDa and ranged from 187.4 kDa to 212.2 kDa;
the bandwidth for β-actin was 9.3 ± 1.2 kDa and ranged
from 45.1 kDa to 54.35 kDa. In these electropherograms,
each AUC is proportional to the amount of protein, allowing
comparisons of P-gp levels between CNI and AD patients.
Utilizing this method, we found that P-gp protein levels in
capillaries isolated from brain tissue of AD patients are 37%
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FIGURE 1 | P-glycoprotein (P-gp) protein expression levels are decreased and P-gp ubiquitination levels are increased in brain capillaries from Alzheimer’s disease
(AD) patients. (A) Representative image of a P-gp-immunostained (green) brain capillary isolated from brain tissue of a cognitive normal individual (CNI); nuclei were
counterstained with DAPI (blue). (B) Negative control (no primary antibody): (B1; green channel); (B2; blue channel); (B3; overlay of green and blue channel) and (B4;
transmitted light channel). (C) Representative WESTM image and (D) electropherogram showing reduced P-gp (blue shaded area) protein expression levels in brain
capillaries isolated from human brain tissue (frontal cortex) of AD patients (n = 3) vs. CNIs (n = 3). (E) Overlay of electropherograms displayed in (D) show a reduction
in the area under the curve (AUC) that represents P-gp protein expression levels (blue shaded area) in brain capillaries from AD patients (red line) relative to CNI (blue
line). In contrast, β-actin levels (orange shaded area) in brain capillaries from AD patients (red line) and CNI (blue line) were the same. (F) Western blot showing that
ubiquitin levels in P-gp-immunoprecipitates are increased in capillaries from AD patients compared to those from CNI.
lower compared to P-gp protein levels in capillaries isolated
from brain samples of CNI (AUC P-gp AD 349670 vs. AUC
Pgp CNI 557147 photons × kDa/s). Figure 1E shows an overlay
of the electropherograms in Figure 1D. This overlay shows
the difference in peak heights and the areas under the curve
(AUC) that represent total protein amount for P-gp and β-actin,
respectively, which is a more accurate approach to quantitate
protein amount than optical density measurements (O’Neill
et al., 2006).
To determine ubiquitinated P-gp levels, we performed
immunoprecipitation experiments with brain capillaries from
brain tissue of CNI and AD patients and observed that
ubiquitination of P-gp was 2.8-fold higher in brain capillaries
from patients with AD compared to CNI (n = 3; p = 0.05,
Figure 1F; Supplementary Figures S1A,B). This indicates that
blood-brain barrier P-gp is highly ubiquitinated in patients
with AD.
PYR41 Prevents Reduction of P-gp
Expression and Activity Levels in hAPP
Mice
Ubiquitination of a target protein is carried out by three enzymes.
First, ubiquitin is activated by the ubiquitin-activating enzyme
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E1. In the second step, ubiquitin is transferred onto the target
protein by the conjugating enzyme E2. This ubiquitin transfer is
completed in a third step by the ubiquitin ligase E3 resulting in
ubiquitination of the target protein.
PYR41 is an E1 ubiquitin-activating enzyme-specific inhibitor
that shows little activity on E2 and E3. PYR41 irreversibly
blocks ubiquitination, thereby preventing ubiquitin-mediated
proteasomal degradation in vitro and in vivo (Yang et al., 2007;
Guan and Ricciardi, 2012). We used PYR41 to test the hypothesis
that blocking ubiquitination protects blood-brain barrier P-gp
from degradation in transgenic hAPP mice in vivo. We dosed
young, 8-week old hAPP mice with 2 mg/kg PYR41 i.p. once
every 3 days for 14 days (Table 1). An additional group of
mice received PYR41 in combination with the P-gp inhibitor
cyclosporin A (CSA; 25 mg/kg, p.o.) on days between dosing
PYR41 alone. These PYR41/CSA-treated mice serve as control
group for P-gp transport activity and are used to account for
PYR41-treatment effects that depend on P-gp transport activity.
WT and hAPP control mice received vehicle. Treatment of
hAPP mice with PYR41 restored P-gp protein expression levels
in brain capillary membranes to levels observed in vehicle-
treated WT mice (Figure 2A). We also observed this effect
in PYR41/CSA-treated animals. Optical density measurements
of P-gp (n = 3, normalized to β-actin) given as percent of
WT control mice (SEM, p-value) are: hAPP: 46 ± 10.5%
(t = 3.52, p = 0.022; ANOVA post hoc test); hAPP-PYR41:
106 ± 11.8% (t = 0.39, p = 0.72; ANOVA post hoc test), and
hAPP-PYR41/CSA: 106 ± 10.4% (t = 0.39, p = 0.70; ANOVA
post hoc test).
Next, we determined P-gp transport activity in isolated brain
capillaries by using a transport assay we previously described
(Hartz et al., 2008, 2010, 2016, 2017). In this assay, freshly
isolated brain capillaries are incubated with the fluorescent
P-gp substrate NBD-cyclosporin A (NBD-CSA, 2 µM) for 1 h
to steady state. Capillaries are then imaged with a confocal
microscope followed by quantitative image analysis of NBD-CSA
fluorescence in the capillary lumen. In brain capillaries with
lower P-gp transport activity compared to control capillaries,
less NBD-CSA is transported into the capillary lumen, resulting
in lower luminal NBD-CSA fluorescence. Thus, the level of
luminal NBD-CSA fluorescence is a measure for P-gp transport
activity.
Figure 2B shows representative confocal images of brain
capillaries isolated from WT mice, hAPP mice, hAPP mice
treated with PYR41 and hAPP mice treated with PYR41/CSA
that were exposed to NBD-CSA. Compared to capillaries from
WT mice, luminal NBD-CSA fluorescence was decreased in
capillaries from hAPPmice and PYR41/CSA-treated hAPPmice,
indicating reduced P-gp transport activity levels. In contrast,
PYR41 treatment maintained luminal NBD-CSA fluorescence
in capillaries from hAPP mice at control levels. Data from
confocal image analysis indicate that specific luminal NBD-CSA
fluorescence in the lumens of brain capillaries from hAPP mice
was reduced by 72% (t = 15.1, p < 0.0001; ANOVA post hoc
test) relative to WT mice (Figure 2C). In contrast, luminal
NBD-CSA fluorescence levels in brain capillaries from PYR41-
treated hAPP mice were similar to levels measured in capillaries
FIGURE 2 | PYR41 prevents reduction of P-gp protein expression and
transport activity in human amyloid precursor protein (hAPP) mice. (A)
Western blot showing that PYR41 treatment restored P-gp protein expression
levels in hAPP mice compared to vehicle-treated wild type (WT) mice; β-actin
was used as protein loading control. (B) Representative confocal images of
brain capillaries isolated from WT, hAPP, hAPP-PYR41 and hAPP-PYR41/CSA
mice after a 1 h incubation (steady state) with the fluorescent, P-gp-specific
substrate NBD-CSA (2 µM). (C) Data from ImageJ analysis of confocal images
in (B) show that luminal NBD-CSA fluorescence was significantly reduced in
brain capillaries from hAPP and hAPP-PYR41/CSA mice relative to brain
capillaries from WT and hAPP-PYR41 mice. Specific NBD-CSA fluorescence
is the difference between total luminal fluorescence and fluorescence in the
presence of the P-gp-specific inhibitor PSC833, representing transport activity
that is specific to P-gp. Data are mean ± SEM (n = 10 capillaries per
treatment group); arbitrary fluorescence units (scale 0–255). Statistics:
∗∗∗p < 0.001 analysis of variance (ANOVA), significantly lower than WT control
group.
from WT mice (t = 0.3, p = 0.81; ANOVA post hoc test).
In brain capillaries from PYR41-treated hAPP mice that also
received CSA to control for P-gp transport activity luminal
NBD-CSA fluorescence was reduced by 68% relative to WT
mice; this reduction is comparable to that seen in vehicle-
treated hAPP mice (t = 13.0, p < 0.0001; ANOVA post hoc
test).
We repeated this experiment using fluorescein-hAβ42 (FL-
hAβ42) to test the ability of P-gp to transport Aβ into the
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lumen of brain capillaries. Figure 3A shows representative
images of isolated brain capillaries incubated to steady state for
1 h with 5 µM FL-hAβ42. Image analysis shows that luminal
FL-hAβ42 fluorescence was reduced to 32.6 ± 9.2% (t = 6.4,
p < 0.0001; ANOVA post hoc test) in capillaries from hAPP
mice relative to capillaries from WT mice (Figure 3B). Luminal
FL-hAβ42 fluorescence levels in brain capillaries isolated from
PYR41-treated hAPPmice was comparable to fluorescence levels
observed in capillaries from WT mice (t = 0.6, p = 0.54;
ANOVA post hoc test). In contrast, FL-hAβ42 fluorescence levels
in capillary lumens from PYR41/CSA-treated control mice were
significantly reduced (t = 6.87, p< 0.0001; ANOVA post hoc test),
which was comparable to luminal fluorescence levels in brain
capillary lumens of untreated hAPP mice.
FIGURE 3 | PYR41 treatment restores P-gp-mediated hAβ42 transport in
hAPP mice. (A) Representative confocal images of isolated brain capillaries
from WT, hAPP, hAPP-PYR41 and hAPP-PYR41/CSA mice after a 1 h
incubation with 5 µM FL-hAβ42. (B) Data from ImageJ analysis of confocal
images in (A) show that luminal FL-hAβ42 levels were significantly reduced in
brain capillaries from hAPP and hAPP-PYR41/CSA mice relative to brain
capillaries from WT and hAPP-PYR41 mice. In contrast, luminal FL-hAβ42
fluorescence levels in brain capillaries from PYR41-treated hAPP mice are
comparable to those in isolated brain capillaries from WT mice indicating that
PYR41-treatment restored P-gp transport activity. Specific FL-hAβ42
fluorescence is the difference between total luminal fluorescence and
fluorescence in the presence of the P-gp-specific inhibitor PSC833,
representing FL-hAβ42 transport into the lumen of brain capillaries that is
specific to P-gp. Data are mean ± SEM (n = 7 capillaries per treatment group);
arbitrary fluorescence units (scale 0–255). Statistics: ∗∗∗p < 0.001 (ANOVA),
significantly lower than WT control group.
Together, the data in Figures 2, 3 demonstrate that
PYR41 treatment of young hAPP mice attenuated reduction of
both P-gp protein expression and transport activity levels. This
suggests that PYR41 prevented P-gp degradation through the
ubiquitin-proteasome system.
PYR41 Treatment of hAPP Mice Prevents
P-gp Ubiquitination in Vivo
PYR41 is a cell-permeable, specific and irreversible inhibitor
of the ubiquitin-activating enzyme E1, which is responsible
for mediating the first step of ubiquitination of proteins that
are proteasome targets. Thus, PYR41 inhibits ubiquitination of
proteins, thereby preventing their degradation by the ubiquitin-
proteasome system. To determine the effect of PYR41 treatment
on the ubiquitination status of P-gp at the blood-brain barrier,
we performed immunoprecipitation experiments with isolated
brain capillaries from PYR41-treated and untreated hAPP mice.
The Western blot in Figure 4A shows that immunoprecipitated
P-gp protein levels were similar in brain capillaries from hAPP
mice and hAPP mice treated with PYR41 and PYR41/CSA. We
observed high levels of ubiquitinated P-gp in isolated capillaries
from hAPP mice. In contrast, brain capillaries isolated from
PYR-41 and PYR41/CSA-treated hAPP mice had no detectable
levels of ubiquitinated P-gp. These data indicate that PYR41
treatment was effective to prevent ubiquitination of P-gp in brain
capillaries.
The Western blot in Figure 4B shows protein expression
levels of P-gp and other proteins involved in Aβ production or
transport, as well as signaling molecules associated with P-gp
reduction. Data from isolated brain capillaries from hAPP mice
showed a reduction in P-gp protein expression levels relative
to P-gp levels in WT mice, an effect that was blocked with
PYR41 and PYR41/CSA treatment. Importantly, PYR41 and
PYR41/CSA treatment did not alter protein expression levels
of other proteins associated with Aβ production (hAPP), Aβ
clearance (LRP1), Aβ transport (RAGE), or the degradation of
P-gp (Nedd-4, 20S Proteasome).
Together, these data demonstrate that PYR41 treatment
prevented P-gp ubiquitination in capillaries isolated from hAPP
mice but did not affect other proteins involved in Aβ production
or transport.
PYR41 Treatment of hAPP Mice Lowers Aβ
Levels
In a next step, we determined the consequences of
PYR41 treatment on Aβ levels in plasma, capillary membranes,
and brain tissue. We measured hAβ40 and hAβ42 levels in plasma
by ELISA and found no difference in hAβ40 and hAβ42 plasma
levels among PYR41-treated, PYR41/CSA-treated, and untreated
hAPP mice (Figures 5A,B). Samples from WT mice were not
included since WT mice do not express human Aβ.
We also immunostained isolated brain capillaries for hAβ40
and hAβ42 to determine capillary-associated Aβ levels. Brain
capillaries isolated from vehicle-treated hAPP mice stained
positive for both Aβ peptides (Figures 6A,B). PYR41-treatment
decreased membrane-associated immunofluorescence of hAβ40
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FIGURE 4 | PYR41 prevents P-gp ubiquitination in hAPP mice. (A) Western
blot showing that treating hAPP mice with PYR41 reduces ubiquitin levels in
P-gp-immunoprecipitates from isolated brain capillaries. P-gp was
immunoprecipitated in capillary samples isolated from hAPP, hAPP-PYR41
and hAPP-PYR41/CSA mice, and examined for P-gp and ubiquitin levels by
Western blotting (brain capillaries isolated from pooled tissue; n = 15 mice per
treatment group). (B) Western blot showing that PYR41 and PYR41/CSA
treatment of mice had only an effect on P-gp protein expression levels,
whereas levels of LRP, RAGE, hAPP, Nedd-4 and the 20S proteasome were
not affected in isolated brain capillaries (pooled tissue; n = 15 mice per
treatment group).
by 16 ± 5.2% (t = 8.9, p < 0.0001; ANOVA post hoc test) and
that of hAβ42 by 20 ± 2.2% (t = 3.1, p = 0.0094; ANOVA post
hoc test) relative to untreated hAPP mice. However, this effect
was not observed in Aβ-immunostained brain capillaries from
PYR41/CSA-treated hAPP mice, indicating that inhibiting P-gp
transport activity with CSA blocks the reduction in Aβ levels in
brain capillaries.
Finally, data from Western blot analyses showed a significant
reduction of hAβ40 and hAβ42 protein levels in brain tissue
samples of PYR41-treated hAPPmice relative to untreated hAPP
mice (Figure 7A). This was not the case in brain tissue from
PYR41-treated mice that also received CSA to control for P-gp
transport activity. Optical density measurements of Western
blots revealed that PYR41 treatment reduced brain hAβ40 levels
by 42 ± 6.8% (t = 6.3, p < 0.003; df = 4, t-test) and hAβ42 levels
by 47 ± 4.5% (t = 10.5, p < 0.0004; df = 4, t-test) compared
to vehicle-treated hAPP mice. Consistent with our Western blot
FIGURE 5 | PYR41 treatment has no effect on Aβ plasma levels. (A) hAβ40
levels (pg/ml) in plasma samples from hAPP mice treated with vehicle, PYR41,
or PYR41/CSA determined by ELISA. Data are given for each animal (hAPP:
n = 12; hAPP-PYR41: n = 14; hAPP-PYR41/CSA: n = 13). (B) hAβ42 plasma
levels (pg/ml) in samples from hAPP mice treated with vehicle (n = 12), PYR41
(n = 14), or PYR41/CSA (n = 13). Statistics: ANOVA; Data between groups are
not significantly different.
results, data from ELISA analysis of brain samples also showed
a reduction in hAβ40 and hAβ42 brain levels in hAPP mice
treated with PYR41. hAβ40 levels were reduced by 53.3 ± 0.51%
(t = 11.4, p = 0.0005; ANOVA post hoc test) and hAβ42 levels
were reduced by 33.3 ± 0.08% (t = 4.9, p = 0.018; ANOVA
post hoc test), respectively (Figures 7B,C). Together these data
indicate that PYR41 treatment prevents P-gp degradation, which
results in a reduction in hAβ40 and hAβ42 brain levels in hAPP
mice.
In summary, our data indicate that blocking P-gp
ubiquitination prevents P-gp degradation, which ultimately
leads to a reduction in Aβ brain levels. Thus, targeting the
ubiquitin-proteasome system early in AD could be a therapeutic
strategy to protect brain capillary P-gp and thereby lower Aβ
brain levels.
DISCUSSION
We recently reported that P-gp protein expression and transport
activity levels are significantly reduced at the blood-brain barrier
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FIGURE 6 | PYR41 treatment reduces Aβ levels in brain capillary membranes. Representative confocal images of (A) hAβ40-immunostained and (B)
hAβ42-immunostained brain capillaries isolated from vehicle-, PYR41- and PYR41/CSA-treated hAPP mice. Data from image analysis with ImageJ show that (C)
hAβ40 and (D) hAβ42 membrane immunofluorescence is lower in capillaries isolated from PYR41-treated hAPP compared to control hAPP mice and mice that
received PYR41/CSA. Data are mean ± SEM (n = 7 brain capillaries per treatment group); shown are arbitrary fluorescence units (scale 0–255). Statistics: ∗∗p < 0.01
(ANOVA), ∗∗∗p < 0.001 (ANOVA) significantly lower than hAPP vehicle-treated mice.
in young, 12-week old hAPP mice that do not display cognitive
deficits yet (Hartz et al., 2010). We also demonstrated that
Aβ40 triggers reduction of P-gp expression and activity levels
by activating the ubiquitin-proteasome system which leads to
degradation of the transporter (Akkaya et al., 2015; Hartz et al.,
2016). One consequence of reduced P-gp levels is impaired Aβ
clearance from brain to blood across the blood-brain barrier
(Hartz et al., 2010). The present study extends our previous
ex vivo findings to an in vivo therapeutic strategy designed
to prevent loss of P-gp by targeting the ubiquitin-proteasome
system.
Here, we report that P-gp protein expression levels are
reduced and P-gp ubiquitination levels are increased in isolated
capillaries from AD patients relative to CNIs (Figure 1).
Further, we show that treatment of 8–12-week old hAPP mice
with PYR41, a specific and irreversible inhibitor of ubiquitin-
activating enzyme E1, prevented degradation of P-gp in brain
capillaries from hAPP mice (Figure 2). P-gp transport activity
levels in PYR41-treated hAPP mice were comparable to those
in control WT mice, and P-gp-mediated Aβ40 transport activity
was also fully restored to control levels in brain capillaries
isolated from PYR41-treated hAPP mice (Figure 3). We found
that PYR41 treatment reduced levels of ubiquitinated P-gp
in brain capillaries from hAPP mice, indicating successful
inhibition of E1 function in vivo (Figure 4A). Other proteins
involved in Aβ production and/or transport were not affected
by PYR41 treatment (Figure 4B). While our data suggest
that PYR41 treatment prevented P-gp ubiquitination in brain
capillaries isolated from hAPP mice without affecting proteins
involved in Aβ production or transport (Figure 4B), we
cannot fully exclude that PYR41 had no effect on other
proteins that could also be involved in Aβ brain accumulation.
PYR41 treatment did not affect Aβ plasma levels in hAPP
mice, but slightly reduced hAβ40 and hAβ42 levels in brain
capillaries (Figures 5, 6). PYR41 treatment did, however,
significantly reduce hAβ brain levels in PYR41-treated hAPP
mice compared to vehicle- and PYR41/CSA-treated hAPP
control mice (Figure 7).
Together, we provide in vivo evidence that inhibiting the
ubiquitin-proteasome system blocks the reduction of P-gp levels
and lowers Aβ brain levels in an AD mouse model. In the
following sections we discuss different aspects of our study and
put our findings in context with existing reports.
The Ubiquitin-Proteasome System Is
Involved in P-gp Regulation
The ubiquitin-proteasome system is responsible for degradation
of proteins, and therefore, essential for proteostasis
(Ciechanover, 1994; Ciechanover and Kwon, 2015). The
first step in protein degradation by the ubiquitin-proteasome
system is ubiquitination of the target protein that is to be
degraded. In a four-step process, a cascade of ubiquitin-
activating, -conjugating, -ligating and -elongating enzymes
(E1–E4) mediate the conjugation of ubiquitin to an amino
group of the target protein. After addition of a polyubiquitin
chain on the target protein, the now ubiquitinated membrane
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FIGURE 7 | PYR41 treatment reduces Aβ brain levels in hAPP mice. (A) Western blots showing PYR41 treatment reduced hAβ40 and hAβ42 protein expression levels
in total brain tissue in hAPP mice compared to vehicle-treated WT mice or hAPP mice treated with PYR41/CSA; β-actin was used as protein loading control. ELISA
analysis of brain tissue revealed that PYR41 significantly reduced protein levels of (B) hAβ40 by 53.3 ± 0.51% and (C) hAβ42 by 33.3 ± 0.08%. Data are
mean ± SEM (pooled tissue from 15 mice per treatment group). Statistics: ∗p < 0.05 and ∗∗∗p < 0.001 (ANOVA), significantly lower than hAPP vehicle-treated mice.
protein is internalized, recognized by the 26S proteasome
complex and is then degraded in an ATP-driven process. The
way proteins are ubiquitinated is complex and multifaceted.
Some proteins are tagged with one ubiquitin molecule in a
process referred to as monoubiquitination. Other proteins
undergo multi-monoubiquitination during which different
amino acid residues of the same target protein receive each one
ubiquitin molecule. In contrast, polyubiquitination describes
a process during which several ubiquitin molecules are
added to one target protein resulting in linear or branched
polyubiquitinated chains with different topologies. Mono-
and polyubiquitination affects proteins in many ways: it can
affect protein activity, promote or prevent protein interactions,
alter protein cellular location or signal protein degradation via
the proteasome.
Our previous work and the present study show that
blood-brain barrier P-gp protein expression levels, and thus,
P-gp transport activity levels, are regulated by the ubiquitin-
proteasome system (Akkaya et al., 2015; Hartz et al., 2016).
Our findings suggest that increased proteasomal degradation
of P-gp is responsible for reduced P-gp expression and
activity levels in AD. Our work is consistent with findings
from other groups showing that the ubiquitin-proteasome
system regulates localization, protein expression, and transport
function of human P-gp (Loo and Clarke, 1998; Zhang et al.,
2004). Katayama et al. (2013) demonstrated in the human
colorectal cancer cell lines HCT-15 and SW620 that FBXO15,
a subunit of the ubiquitin E3 ligase, is a negative regulator
of P-gp protein expression. Data from immunoprecipitation
experiments indicated that FBXO15 binds to P-gp and enhances
ubiquitination of the transporter. FBXO15 knockdown led to
increased P-gp expression and transport activity in both cancer
cell lines. In the same study, Katayama et al. (2013) also
demonstrated that the ubiquitin E3 ligase complex SCFFbx15
recognizes P-gp as a substrate and brings the transporter in
contact with the ubiquitin-conjugating enzyme Ube2r1, which
ubiquitinates P-gp. More recently, Katayama et al. (2016)
showed that inactivating MAPK signaling with small-molecule
inhibitors leads to increased Ube2r1 expression levels, which,
in turn, promotes P-gp degradation through the proteasome.
Ravindranath et al. (2015) showed that the ubiquitin E3-ligase
FBXO21 also catalyzes P-gp ubiquitination, thereby targeting
it for subsequent proteasomal degradation. In addition, Rao
et al. (2006) showed that the E3 ubiquitin ligase, RING finger
protein 2 (RNF2), interacts with the linker region of human
P-gp and the authors demonstrated that co-expression of RNF2
and P-gp results in decreased ATPase activity and proteolytic
protection of the transporter in Sf9 insect cells. Together,
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data from various groups suggest that P-gp expression and
transport activity are regulated by the ubiquitin-proteasome
system.
Our previously published work indicates that Aβ40 triggers
P-gp ubiquitination, resulting in internalization and proteasomal
degradation of the transporter (Hartz et al., 2016). Further,
we have demonstrated that P-gp may be a substrate for the
ubiquitin E3-ligase Nedd-4 (Akkaya et al., 2015). In the present
study, we expand this line of research by inhibiting P-gp
ubiquitination with the ubiquitin-activating enzyme E1 inhibitor
PYR41 in a mouse AD model in vivo and show that blocking
P-gp ubiquitination prevents loss of P-gp and lowers Aβ brain
levels.
In addition to P-gp, other proteins are also thought to
facilitate Aβ transport across the blood-brain barrier such
as the low-density lipoprotein receptor-related protein (LRP;
Deane et al., 2008; Storck et al., 2016). Similar to P-gp,
LRP levels were reduced in brain capillaries from various AD
mouse models and in post-mortem brain tissue from AD
patients (Donahue et al., 2006; Silverberg et al., 2010). Like
P-gp, degradation of LRP is mediated by the proteasome,
however, LRP degradation appears to be independent from
ubiquitination. In this regard, Melman et al. (2002) have
demonstrated that tyrosine and di-leucine motifs within the
LRP cytoplasmic tail mediate rapid endocytosis followed by
proteasomal degradation, a process that does not require
ubiquitination. Deane et al. (2004) showed that Aβ enhanced
LRP proteasomal degradation in brain capillaries of 6–9-month
old hAPP mice with cognitive impairment. The low LRP levels
and the behavior deficits in these mice are consistent with
reduced LRP levels in Aβ-accumulating mice and patients
with AD and familial cerebrovascular β-amyloidosis (Deane
et al., 2004). These findings suggest that reduced expression
and activity levels of P-gp and LRP in brain capillaries, which
contributes to Aβ pathology, result from similar augmentations
of the ubiquitin-proteasome system, where P-gp is affected by
enhanced ubiquitination and LRP is affected by enhanced direct
proteasomal degradation.
The Ubiquitin-Proteasome System in
Alzheimer’s Disease
Protein misfolding, protein mishandling and deficits in protein
quality control often drive neurodegenerative disease pathology
(Urushitani et al., 2002; Kabashi et al., 2004; Ross and Pickart,
2004). These abnormal processes can lead to accumulation
of Aβ in the brain and intraneuronal aggregation of hyper-
phosphorylated tau protein, both of which are hallmarks of
AD (Oddo, 2008; Riederer et al., 2011; Morawe et al., 2012;
Hong et al., 2014; Gentier and van Leeuwen, 2015; Gadhave
et al., 2016). Numerous studies reported that the activity of the
ubiquitin-proteasome system is reduced in AD. For example,
data from post-mortem studies of patients with late-stage
AD showed accumulation of ubiquitin in both plaques and
tangles and increased levels of a variety of ubiquinated proteins
(Perry et al., 1987; Keck et al., 2003). One explanation for
this finding is a dysfunctional ubiquitin-proteasome system,
where ubiquitinated proteins accumulate in the tissue but
are not further degraded by the proteasome. Indeed, Keller
et al. (2000) observed a significant decrease in proteasome
activity in the hippocampus, parahippocampal gyrus, middle
temporal gyri, and inferior parietal lobule of patients with
AD compared to cognitive normal individuals. Moreover, in
AD, the proteolytic activity of the 26S proteasome appears
to be impaired, resulting in oxidation and downregulation of
ubiquitin C-terminal hydrolase 1 (UCH1), which is responsible
for ubiquitin turnover (Almeida et al., 2006). Further, mutant
ubiquitin, UBB+1, is a hallmark of various neurodegenerative
diseases. Elevated UBB+1 levels in the brain directly inhibit
proteasome activity, which is thought to lead to Aβ accumulation
and hyper-phosphorylated tau, and thus, constitutes a risk
factor for AD (Lindsten et al., 2002; van Leeuwen et al., 2006;
Shabek et al., 2009; Dennissen et al., 2010; Ciechanover and
Kwon, 2015). Collectively, growing evidence suggests that a
dysfunctional ubiquitin-proteasome system contributes to AD
pathology. However, little is known about the mechanisms that
drive irregular activity of the complex ubiquitin-proteasome
system, what brain regions and brain cell types are affected
is not fully understood, and during which disease stages
these changes occur is unclear. In contrast to brain tissue,
our previous reports and the present study indicate that in
the brain capillaries of the blood-brain barrier, the ubiquitin-
proteasome system is overly active, leading to ubiquitination
and degradation of membrane proteins such as P-gp (Akkaya
et al., 2015; Hartz et al., 2016). The discrepancy between
impaired proteasome activity in brain tissue and increased
proteasome activity in brain capillary endothelial cells could
be due to tissue-specific differences of the 20S proteasome.
This explanation is supported by multiple reports showing that
enzymes of the ubiquitin pathway (E1–4) are expressed in a
tissue-specific manner and that alterations in ubiquitin ligase
activity, proteasome subunit composition, and proteasome-
interacting proteins are tissue-specific and adapt to functional
needs in their respective tissues (Patel and Majetschak, 2007;
Mayor and Peng, 2012; Kniepert and Groettrup, 2014; Ortega
and Lucas, 2014).
In addition to tissue-specific differences, it is possible that
proteasome activity changes with age, and thus, could be time-
or even context-dependent. Current studies in our laboratory
are aimed at determining levels of ubiquitination and 20S
proteasome activity in hAPP mice at different ages.
The Ubiquitin-Proteasome System as a
Therapeutic Target
Collectively, our previous and present findings suggest that
the ubiquitin-proteasome system is involved in reducing P-gp
protein expression and transport activity levels in AD. Based
on data from our studies, preventing P-gp loss by targeting
the ubiquitin-proteasome pathway could potentially serve as
therapeutic strategy to protect P-gp from degradation, reduce
Aβ brain accumulation, and slow AD progression. While
targeting ubiquitination may represent a new therapeutic
strategy, developing drugs that target the ubiquitin activating,
conjugating, ligating and elongating enzymes E1–E4 remains a
challenge. These enzymes do not have a well-defined catalytic
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pocket, which makes the design of specific small molecule
inhibitors difficult (Nalepa et al., 2006). Further, ubiquitination
is a complex process that depends on dynamic protein-protein
interactions that are difficult to disrupt with small molecules. In
addition, as the name indicates, ubiquitination is a ubiquitous
process present in all cells of the body, and thus, selectively
targeting one tissue and not others is challenging. Consequently,
FDA-approved drugs that specifically and selectively block
ubiquitination are currently not available.
A different therapeutic option could be to target the
proteasome itself. Currently, two FDA-approved small-molecule
20S proteasome inhibitors are on the market for cancer therapy:
bortezomib (Velcader) and carfilxomib (Krypolisr). Both
drugs show efficacy in multiple myeloma with manageable
pharmacokinetic properties and a relatively low side effect
profile. Since the 20S proteasome subunit is the proteolytic core
of the multi-subunit 26S proteasome proteolytic complex, both
inhibitors—bortezomib and carfilxomib—also affect the activity
of the entire 26S proteasome complex. While targeting the
proteasome is an option, two points need more reflection. First,
the potential inverse relationship between dysfunction of the
ubiquitin-proteasome system in the brain relative to the blood-
brain barrier must be taken into consideration. Inhibiting the 20S
proteasome may be particularly beneficial in the early stages of
AD to prevent P-gp loss and facilitate Aβ clearance. However,
20S proteasome inhibition may be detrimental in later AD stages
when the ubiquitin-proteasome system is greatly impaired in the
brain. Second, 20S proteasome inhibition is only feasible and can
only be fully taken advantage of when AD is diagnosed early.
While significant efforts have been made to identify biomarkers
and develop novel imaging techniques that allow early AD
diagnosis, no tools are currently available in the clinic and early
AD diagnosis, prior to the appearance of behavioral symptoms,
remains a formidable challenge.
In summary, in the present in vivo study we show that
preventing ubiquitination of P-gp at the blood-brain barrier
protects the transporter from degradation, which substantially
lowers Aβ brain levels in an ADmousemodel. These data suggest
a novel therapeutic avenue that helps protect P-gp by limiting
Aβ-induced P-gp degradation for improved Aβ clearance across
the blood-brain barrier in AD.
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